An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. In Silico Analysis of Gene Expression Profiles of Selenoproteins
2.2. Cell Lines
2.3. RNA Preparation and RT-qPCR
2.4. Western Blot Analysis
2.5. Tissue Samples
2.6. Functional Analysis
2.7. Human Interactome Construction
2.8. TNBC Network Construction and Selenoprotein Network Analysis
3. Results
3.1. In Silico Analysis of Selenoprotein Expression in TNBC Cell Lines
3.2. In Vitro Analysis of Selenoprotein Gene Expression Profile in Breast Cancer Cells
3.3. Selenoprotein Gene Expression Evaluation in TNBC Tissues
3.4. Identification of a Strict Correlation between SELENOS and VCP/p97 by Network Analysis
3.5. VCP/p97 and SELENOS Correlated Overexpression in TNBC
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chue, B.M.; La Course, B.D. Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease. Medicine 2019, 98, e15302. [Google Scholar] [CrossRef] [PubMed]
- Cocco, S.; Piezzo, M.; Calabrese, A.; Cianniello, D.; Caputo, R.; Lauro, V.D.; Fusco, G.; Gioia, G.D.; Licenziato, M.; De Laurentiis, M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int. J. Mol. Sci. 2020, 21, 4579. [Google Scholar] [CrossRef] [PubMed]
- Huo, X.; Shen, G.; Liu, Z.; Liang, Y.; Li, J.; Zhao, F.; Ren, D.; Zhao, J. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Oncol. Hematol. 2021, 168, 103530. [Google Scholar] [CrossRef] [PubMed]
- Labunskyy, V.M.; Hatfield, D.L.; Gladyshev, V.N. Selenoproteins: Molecular pathways and physiological roles. Physiol. Rev. 2014, 94, 739–777. [Google Scholar] [CrossRef] [Green Version]
- Reeves, M.A.; Hoffmann, P.R. The human selenoproteome: Recent insights into functions and regulation. Cell. Mol. Life Sci. 2009, 66, 2457–2478. [Google Scholar] [CrossRef] [Green Version]
- Short, S.P.; Williams, C.S. Selenoproteins in Tumorigenesis and Cancer Progression. Adv. Cancer Res. 2017, 136, 49–83. [Google Scholar]
- Jiang, H.; Shi, Q.Q.; Ge, L.Y.; Zhuang, Q.F.; Xue, D.; Xu, H.Y.; He, X.Z. Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway. Cancer Med. 2019, 8, 4836–4844. [Google Scholar] [CrossRef]
- Yu, Y.P.; Yu, G.; Tseng, G.; Cieply, K.; Nelson, J.; Defrances, M.; Zarnegar, R.; Michalopoulos, G.; Luo, J.H. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 2007, 67, 8043–8050. [Google Scholar] [CrossRef] [Green Version]
- Handy, D.E.; Lubos, E.; Yang, Y.; Galbraith, J.D.; Kelly, N.; Zhang, Y.Y.; Leopold, J.A.; Loscalzo, J. Glutathione peroxidase-1 regulates mitochondrial function to modulate redox-dependent cellular responses. J. Biol. Chem. 2009, 284, 11913–11921. [Google Scholar] [CrossRef] [Green Version]
- Marciel, M.P.; Hoffmann, P.R. Selenoproteins and metastasis. Adv. Cancer Res. 2017, 136, 85–108. [Google Scholar]
- Varlamova, E.G. Participation of selenoproteins localized in the ER in the processes occurring in this organelle and in the regulation of carcinogenesis-associated processes. J. Trace Elem. Med. Biol. 2018, 48, 172–180. [Google Scholar] [CrossRef] [PubMed]
- Capone, F.; Polo, A.; Sorice, A.; Budillon, A.; Costantini, S. Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer. Int. J. Mol. Sci. 2020, 21, 6694. [Google Scholar] [CrossRef] [PubMed]
- Sandsveden, M.; Nilsson, E.; Borgquist, S.; Rosendahl, A.H.; Manjer, J. Prediagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics. Int. J. Cancer. 2020, 147, 2424–2436. [Google Scholar] [CrossRef]
- Debski, M.G.; Pachucki, J.; Ambroziak, M.; Olszewski, W.; Bar-Andziak, E. Human breast cancer tissue expresses high level of type 1 5′-deiodinase. Thyroid 2007, 17, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Shin, B.; Feser, R.; Nault, B.; Hunter, S.; Maiti, S.; Ugwuagbo, K.C.; Majumder, M. miR526b and miR655 Induce Oxidative Stress in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 4039. [Google Scholar] [CrossRef] [Green Version]
- Leone, A.; Roca, M.S.; Ciardiello, C.; Costantini, S.; Budillon, A. Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. Oxid. Med. Cell. Longev. 2017, 2017, 2597581. [Google Scholar] [CrossRef] [Green Version]
- Méplan, C. Selenium and chronic diseases: A nutritional genomics perspective. Nutrients 2015, 7, 3621–3651. [Google Scholar] [CrossRef]
- Pellatt, A.J.; Wolff, R.K.; John, E.M.; Torres-Mejia, G.; Hines, L.M.; Baumgartner, K.B.; Giuliano, A.R.; Lundgreen, A.; Slattery, M.L. SEPP1 influences breast cancer risk among women with greater native american ancestry: The breast cancer health disparities study. PLoS ONE 2013, 8, e80554. [Google Scholar] [CrossRef] [Green Version]
- Jablonska, E.; Gromadzinska, J.; Peplonska, B.; Fendler, W.; Reszka, E.; Krol, M.B.; Wieczorek, E.; Bukowska, A.; Gresner, P.; Galicki, M.; et al. Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1. BMC Cancer 2015, 15, 657. [Google Scholar] [CrossRef] [Green Version]
- Rusolo, F.; Capone, F.; Pasquale, R.; Angiolillo, A.; Colonna, G.; Castello, G.; Costantini, M.; Costantini, S. Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. Oncol. Lett. 2017, 13, 2411–2417. [Google Scholar] [CrossRef]
- Nunziata, C.; Polo, A.; Sorice, A.; Capone, F.; Accardo, M.; Guerriero, E.; Marino, F.Z.; Orditura, M.; Budillon, A.; Costantini, S. Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. Sci. Rep. 2019, 9, 16131. [Google Scholar] [CrossRef] [Green Version]
- Van den Boom, J.; Meyer, H. VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling. Mol. Cell. 2018, 69, 182–194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fu, Q.; Jiang, Y.; Zhang, D.; Liu, X.; Guo, J.; Zhao, J. Valosin-containing protein (VCP) promotes the growth.; invasion.; and metastasis of colorectal cancer through activation of STAT3 signaling. Mol. Cell. Biochem. 2016, 418, 189–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, W.; Li, D.; Xiao, L. Upregulation of valosin-containing protein (VCP) is associated with poor prognosis and promotes tumor progression of orbital B-cell lymphoma. OncoTargets Ther. 2018, 12, 243–253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.H.; Kwon, J.H.; Jeon, Y.H.; Ko, K.Y.; Lee, S.R.; Kim, I.Y. Pro178 and Pro183 of selenoprotein S are essential residues for interaction with p97(VCP) during endoplasmic reticulum-associated degradation. J. Biol. Chem. 2014, 289, 13758–13768. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.H.; Park, K.J.; Jang, J.K.; Jeon, Y.H.; Ko, K.Y.; Kwon, J.H.; Lee, S.R.; Kim, I.Y. Selenoprotein S-dependent Selenoprotein K Binding to p97(VCP) Protein Is Essential for Endoplasmic Reticulum-associated Degradation. J. Biol. Chem. 2015, 290, 29941–29952. [Google Scholar] [CrossRef] [Green Version]
- Ghandi, M.; Huang, F.W.; Jané-Valbuena, J.; Kryukov, G.V.; Lo, C.C.; McDonald, E.R., 3rd; Barretina, J.; Gelfand, E.T.; Bielski, C.M.; Li, H.; et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 2019, 569, 503–508. [Google Scholar] [CrossRef]
- Duan, Q.; Flynn, C.; Niepel, M.; Hafner, M.; Muhlich, J.L.; Fernandez, N.F.; Rouillard, A.D.; Tan, C.M.; Chen, E.Y.; Golub, T.R.; et al. LINCS Canvas Browser: Interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014, 42, W449–W460. [Google Scholar] [CrossRef]
- Vempati, U.D.; Chung, C.; Mader, C.; Koleti, A.; Datar, N.; Vidović, D.; Wrobel, D.; Erickson, S.; Muhlich, J.L.; Berriz, G.; et al. Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS). J. Biomol. Screen. 2014, 19, 803–816. [Google Scholar] [CrossRef] [Green Version]
- Bairoch, A. The Cellosaurus, a cell line knowledge resource. J. Biomol. Tech. 2018, 29, 25–38. [Google Scholar] [CrossRef]
- Jiang, G.; Zhang, S.; Yazdanparast, A.; Li, M.; Pawar, A.V.; Liu, Y.; Inavolu, S.M.; Cheng, L. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genom. 2016, 17 (Suppl. S7), 525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Rodriguez, I.P.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017, 19, 649–658. [Google Scholar] [CrossRef] [PubMed]
- Goswami, C.P.; Nakshatri, H. PROGgeneV2: Enhancements on the existing database. BMC Cancer 2014, 14, 970. [Google Scholar] [CrossRef] [Green Version]
- Milone, M.R.; Pucci, B.; Colangelo, T.; Lombardi, R.; Iannelli, F.; Colantuoni, V.; Sabatino, L.; Budillon, A. Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. Mol. Oncol. 2016, 10, 1344–1362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
- Romero-Calvo, I.; Ocón, B.; Martínez-Moya, P.; Suárez, M.D.; Zarzuelo, A.; Martínez-Augustin, O.; de Medina, F.S. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal. Biochem. 2010, 401, 318–320. [Google Scholar] [CrossRef]
- Sinicrope, F.A.; Ruan, S.B.; Cleary, K.R.; Stephens, L.C.; Lee, J.J.; Levin, B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995, 55, 237–241. [Google Scholar]
- Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef] [Green Version]
- Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef]
- Orchard, S.; Ammari, M.; Aranda, B.; Breuza, L.; Briganti, L.; Broackes-Carter, F.; Campbell, N.H.; Chavali, G.; Chen, C.; del-Toro, N.; et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014, 42, D358–D363. [Google Scholar] [CrossRef] [Green Version]
- Orchard, S.; Kerrien, S.; Abbani, S.; Aranda, B.; Bhate, J.; Bidwell, S.; Bridge, A.; Briganti, L.; Brinkman, F.S.; Cesareni, G.; et al. Protein interaction data curation: The International Molecular Exchange (IMEx) consortium. Nat. Methods 2012, 9, 345–350. [Google Scholar] [CrossRef] [PubMed]
- Prieto, C.; De Las Rivas, J. APID: Agile Protein Interaction DataAnalyzer. Nucleic Acids Res. 2006, 34, W298–W302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Assenov, Y.; Ramírez, F.; Schelhorn, S.E.; Lengauer, T.; Albrecht, M. Computing topological parameters of biological networks. Bioinformatics 2008, 24, 282–284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chin, C.H.; Chen, S.H.; Wu, H.H.; Ho, C.W.; Ko, M.T.; Lin, C.Y. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014, 8 (Suppl. S4), S11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, E.; Choi, A.; Jun, Y.; Kim, N.; Yook, J.I.; Kim, S.Y.; Lee, S.; Kang, S.W. Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling. Redox Biol. 2020, 29, 101391. [Google Scholar] [CrossRef]
- Wang, Y.; Fang, W.; Huang, Y.; Hu, F.; Ying, Q.; Yang, W.; Xiong, B. Reduction of selenium-binding protein 1 sensitizes cancer cells to selenite via elevating extracellular glutathione: A novel mechanism of cancer-specific cytotoxicity of selenite. Free Radic. Biol. Med. 2015, 79, 186–196. [Google Scholar] [CrossRef]
- Sisti, A.; Huayllani, M.T.; Boczar, D.; Restrepo, D.J.; Spaulding, A.C.; Emmanuel, G.; Bagaria, S.P.; McLaughlin, S.A.; Parker, A.S.; Forte, A.J. Breast cancer in women: A descriptive analysis of the national cancer database. Acta Biomed. 2020, 91, 332–341. [Google Scholar]
- Garrido-Castro, A.C.; Lin, N.U.; Polyak, K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019, 9, 176–198. [Google Scholar] [CrossRef] [Green Version]
- Jardim, B.V.; Moschetta, M.G.; Leonel, C.; Gelaleti, G.B.; Regiani, V.R.; Ferreira, L.C.; Lopes, J.R.; Zuccari, D.A. Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study. Oncol. Rep. 2013, 30, 1119–1128. [Google Scholar] [CrossRef] [Green Version]
- Cecerska-Heryć, E.; Surowska, O.; Heryć, R.; Serwin, N.; Napiontek-Balińska, S.; Dołęgowska, B. Are antioxidant enzymes essential markers in the diagnosis and monitoring of cancer patients—A review. Clin. Biochem. 2021, 93, 1–8. [Google Scholar] [CrossRef]
- Yu, M.; Gai, C.; Li, Z.; Ding, D.; Zheng, J.; Zhang, W.; Lv, S.; Li, W. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019, 110, 3173–31829. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, X.; Sui, S.; Wang, L.; Li, H.; Zhang, L.; Xu, S.; Zheng, X. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J. Cell. Physiol. 2020, 235, 3425–3437. [Google Scholar] [CrossRef] [PubMed]
- Lee, N.; Carlisle, A.E.; Peppers, A.; Park, S.J.; Doshi, M.B.; Spears, M.E.; Kim, D. xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers. Antioxidants 2021, 10, 317. [Google Scholar] [CrossRef] [PubMed]
- Friedmann Angeli, J.P.; Krysko, D.V.; Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 2019, 19, 405–414. [Google Scholar] [CrossRef] [PubMed]
- Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014, 156, 317–331. [Google Scholar] [CrossRef] [Green Version]
- Hunter, S.; Nault, B.; Ugwuagbo, K.C.; Maiti, S.; Majumder, M. Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer. Cancers (Basel) 2019, 11, 938. [Google Scholar] [CrossRef] [Green Version]
- Cadenas, C.; Franckenstein, D.; Schmidt, M.; Gehrmann, M.; Hermes, M.; Geppert, B.; Schormann, W.; Maccoux, L.J.; Schug, M.; Schumann, A.; et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res. 2010, 12, R44. [Google Scholar] [CrossRef] [Green Version]
- Stafford, W.C.; Peng, X.; Olofsson, M.H.; Zhang, X.; Luci, D.K.; Lu, L.; Cheng, Q.; Trésaugues, L.; Dexheimer, T.S.; Coussens, N.P.; et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci. Transl. Med. 2018, 10, eaaf7444. [Google Scholar] [CrossRef] [Green Version]
- Lee, D.; Xu, I.M.; Chiu, D.K.; Leibold, J.; Tse, A.P.; Bao, M.H.; Yuen, V.W.; Chan, C.Y.; Lai, R.K.; Chin, D.W.; et al. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology 2019, 69, 1768–1786. [Google Scholar] [CrossRef]
- Yin, C.; Dai, X.; Huang, X.; Zhu, W.; Chen, X.; Zhou, Q.; Wang, C.; Zhao, C.; Zou, P.; Liang, G.; et al. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model. J. Cell. Mol. Med. 2019, 23, 2194–2206. [Google Scholar] [CrossRef] [Green Version]
- Raninga, P.V.; Lee, A.C.; Sinha, D.; Shih, Y.Y.; Mittal, D.; Makhale, A.; Bain, A.L.; Nanayakarra, D.; Tonissen, K.F.; Kalimutho, M.; et al. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triplenegative breast cancer. Int. J. Cancer 2020, 146, 123–136. [Google Scholar] [CrossRef] [PubMed]
- Hughes, D.J.; Kunická, T.; Schomburg, L.; Liška, V.; Swan, N.; Souček, P. Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer. Nutrients 2018, 10, 1812. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, Y.; Shibata, Y.; Yun, C.; Ron, D.; Rapoport, T.A. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004, 429, 841–847. [Google Scholar] [CrossRef] [PubMed]
- Curran, J.E.; Jowett, J.B.; Elliott, K.S.; Gao, Y.; Gluschenko, K.; Wang, J.; Abel Azim, D.M.; Cai, G.; Mahaney, M.C.; Comuzzie, A.G.; et al. Genetic variation in selenoprotein S influences inflammatory response. Nat. Genet. 2005, 37, 1234–1241. [Google Scholar] [CrossRef] [Green Version]
- Hariharan, S.; Dharmaraj, S. Selenium and selenoproteins: It’s role in regulation of inflammation. Inflammopharmacology 2020, 28, 667–695. [Google Scholar] [CrossRef]
- Sisinni, L.; Pietrafesa, M.; Lepore, S.; Maddalena, F.; Condelli, V.; Esposito, F.; Landriscina, M. Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance. Int. J. Mol. Sci. 2019, 20, 857. [Google Scholar] [CrossRef] [Green Version]
- Howley, B.V.; Link, L.A.; Grelet, S.; El-Sabban, M.; Howe, P.H. A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer. Oncogene 2018, 37, 1308–1325. [Google Scholar] [CrossRef]
- Amini, G.; Salehi, R.; Moshtaghi, A.A.; Kazemi, M.; Behjati, M.; Khosravi, S. Evaluation of SEPP1 and Selenoprotein S Gene Polymorphisms (rs7579 and rs34713741) in Relation to Colorectal Cancer Susceptibility in Subset of Iranian Population: A Case-control Study. Adv. Biomed. Res. 2019, 8, 47. [Google Scholar]
- Mao, H.; Cui, R.; Wang, X. Association analysis of selenoprotein S polymorphisms in chines Han with susceptibility to gastric cancer. Int. J. Clin. Exp. Med. 2015, 8, 10993–10999. [Google Scholar]
- Xia, D.; Tang, W.K.; Ye, Y. Structure and function of the AAA+ ATPase p97/Cdc48p. Gene 2016, 583, 64–77. [Google Scholar] [CrossRef] [Green Version]
- Huryn, D.M.; Kornfilt, D.J.P.; Wipf, P. p97: An Emerging Target for Cancer, Neurodegenerative Diseases, and Viral Infections. J. Med. Chem. 2020, 63, 1892–1907. [Google Scholar] [CrossRef] [PubMed]
- Nishita, M.; Park, S.Y.; Nishio, T.; Kamizaki, K.; Wang, Z.; Tamada, K.; Takumi, T.; Hashimoto, R.; Otani, H.; Pazour, G.J.; et al. Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness. Sci. Rep. 2017, 7, 1. [Google Scholar] [CrossRef] [PubMed]
- Costantini, S.; Capone, F.; Polo, A.; Bagnara, P.; Budillon, A. Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer. Int. J. Mol. Sci. 2021, 22, 10177. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Li, K.; Lin, Y.; Xing, F.; Xiao, X.; Cai, J.; Zhu, W.; Liang, J.; Tan, Y.; Fu, L.; et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 2017, 9, eaam7996. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Xie, X.; Wang, X.; Wen, T.; Zhao, C.; Liu, H.; Zhao, B.; Zhu, Y. Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors. Bioorg. Med. Chem. 2021, 38, 116114. [Google Scholar] [CrossRef]
- Shi, X.; Zhu, K.; Ye, Z.; Yue, J. VCP/p97 targets the nuclear export and degradation of p27Kip1 during G1 to S phase transition. FASEB J. 2020, 34, 5193–5207. [Google Scholar] [CrossRef] [Green Version]
- Fu, X.; Shi, Y.; Qi, T.; Qiu, S.; Huang, Y.; Zhao, X.; Sun, Q.; Lin, G. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal. Transduct. Target Ther. 2020, 5, 262. [Google Scholar] [CrossRef]
- Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Sakon, M.; Kameyama, M.; Imaoka, S.; Sekimoto, M.; Nakamori, S.; Monden, M.; Aozasa, K. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin. Cancer Res. 2004, 10, 651–657. [Google Scholar] [CrossRef] [Green Version]
- Cui, Y.; Niu, M.; Zhang, X.; Zhong, Z.; Wang, J.; Pang, D. High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. Tumor Biol. 2015, 36, 9919–9927. [Google Scholar] [CrossRef]
- Li, C.; Huang, Y.; Fan, Q.; Quan, H.; Dong, Y.; Nie, M.; Wang, J.; Xie, F.; Ji, J.; Zhou, L.; et al. p97/VCP is highly expressed in the stem-like cells of breast cancer and controls cancer stemness partly through the unfolded protein response. Cell Death Dis. 2021, 12, 286. [Google Scholar] [CrossRef]
- Gao, Y.; Pagnon, J.; Feng, H.C.; Konstantopolous, N.; Jowett, J.B.; Walder, K.; Collier, G.R. Secretion of the glucose-regulated selenoprotein SEPS1 from hepatoma cells. Biochem. Biophys. Res. Commun. 2007, 356, 636–641. [Google Scholar] [CrossRef] [PubMed]
- Yu, S.S.; Men, L.L.; Wu, J.L.; Huang, L.W.; Xing, Q.; Yao, J.J.; Wang, Y.B.; Song, G.R.; Guo, H.S.; Sun, G.H.; et al. The source of circulating selenoprotein S and its association with type 2 diabetes mellitus and atherosclerosis: A preliminary study. Cardiovasc. Diabetol. 2016, 15, 70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laguë, M.N.; Romieu-Mourez, R.; Bonneil, É.; Boyer, A.; Pouletty, N.; Mes-Masson, A.M.; Thibault, P.; Nadeau, M.È.; Boerboom, D. Proteomic profiling of a mouse model for ovarian granulosa cell tumor identifies VCP as a highly sensitive serum tumor marker in several human cancers. PLoS ONE 2012, 7, e42470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chapman, E.; Maksim, N.; de la Cruz, F.; La Clair, J.J. Inhibitors of the AAA+ chaperone p97. Molecules 2015, 20, 3027–3049. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Segura-Cabrera, A.; Tripathi, R.; Zhang, X.; Gui, L.; Chou, T.F.; Komurov, K. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase. Sci. Rep. 2017, 7, 44912. [Google Scholar] [CrossRef] [Green Version]
- Leinonen, H.; Cheng, C.; Pitkänen, M.; Sander, C.L.; Zhang, J.; Saeid, S.; Turunen, T.; Shmara, A.; Weiss, L.; Ta, L.; et al. A p97/valosin-containing protein inhibitor drug CB-5083 has a potent but reversible. J. Pharmacol. Exp. Ther. 2021, 378, 31–41. [Google Scholar] [CrossRef]
- Tang, W.K.; Odzorig, T.; Jin, W.; Xia, D. Structural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083. Mol. Pharmacol. 2019, 95, 286–293. [Google Scholar] [CrossRef] [Green Version]
- Wang, F.; Li, S.; Gan, T.; Stott, G.M.; Flint, A.; Chou, T.F. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy. ChemMedChem 2020, 15, 685–694. [Google Scholar] [CrossRef]
Patient Characteristics | Number of Patients |
---|---|
Age (mean ± st.dev.) | 52.6 ± 13.5 |
primitive TNBC | 30 |
histotype | 29: no special type; 1: metaplastic |
grading | grade 2: 10; grade 3: 20 |
Ki67 (range, mean ± st.dev) | grade 2: 10–50%, 28.9 ± 13.3% |
grade 3: 25–70%, 44.9 ± 15.8% | |
Lymphnode status (pN) | grade 2: 8pN0, 2pN1a |
grade 3: 12pN0, 1pN1, 4pN1a, 1pN1c, 1pN2, 1pN2a | |
Tumor size (pT) | grade 2: 1pT1a, 2pT1b, 3pT1c, 3pT2, 1pT3 |
grade 3: 9pT1c, 9pT2, 1pT3, 1pT4a | |
Status | 23 (Live); 7 (Dead) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Costantini, S.; Polo, A.; Capone, F.; Accardo, M.; Sorice, A.; Lombardi, R.; Bagnara, P.; Zito Marino, F.; Amato, M.; Orditura, M.; et al. An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. Cancers 2022, 14, 646. https://doi.org/10.3390/cancers14030646
Costantini S, Polo A, Capone F, Accardo M, Sorice A, Lombardi R, Bagnara P, Zito Marino F, Amato M, Orditura M, et al. An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. Cancers. 2022; 14(3):646. https://doi.org/10.3390/cancers14030646
Chicago/Turabian StyleCostantini, Susan, Andrea Polo, Francesca Capone, Marina Accardo, Angela Sorice, Rita Lombardi, Palmina Bagnara, Federica Zito Marino, Martina Amato, Michele Orditura, and et al. 2022. "An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer" Cancers 14, no. 3: 646. https://doi.org/10.3390/cancers14030646